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Cobblestone lissencephaly is a peculiar brain malformation with characteristic radiological anomalies. It is defined as cortical dysplasia
that results when neuroglial overmigration into the arachnoid space forms an extracortical layer that produces agyria and/or a ‘‘cobble-
stone’’ brain surface and ventricular enlargement. Cobblestone lissencephaly is pathognomonic of a continuum of autosomal-recessive
diseases characterized by cerebral, ocular, andmuscular deficits. These includeWalker-Warburg syndrome,muscle-eye-brain disease, and
Fukuyama muscular dystrophy. Mutations in POMT1, POMT2, POMGNT1, LARGE, FKTN, and FKRP identified these diseases as alpha-
dystroglycanopathies. Our exhaustive screening of these six genes, in a cohort of 90 fetal cases, led to the identification of a mutation
in only 53% of the families, suggesting that other genesmight also be involved.We therefore decided to perform a genome-wide study in
two multiplex families. This allowed us to identify two additional genes: TMEM5 and ISPD. Because TMEM has a glycosyltransferase
domain and ISPD has an isoprenoid synthase domain characteristic of nucleotide diP-sugar transferases, these two proteins are thought
to be involved in the glycosylation of dystroglycan. Further screening of 40 families with cobblestone lissencephaly identified nonsense
and frameshift mutations in another four unrelated cases for each gene, increasing the mutational rate to 64% in our cohort. All these
cases displayed a severe phenotype of cobblestone lissencephaly A. TMEM5mutations were frequently associated with gonadal dysgen-
esis and neural tube defects, and ISPD mutations were frequently associated with brain vascular anomalies.Cobblestone lissencephaly (cobblestone-LIS) is a peculiar
brain malformation with characteristic radiological anom-
alies. It is defined as cerebral cortical dysplasia with an
irregular limit between the white and gray matter, dysmye-
lination, severe dysplastic cerebellum with cysts, and
brainstem hypoplasia.1 Cortical malformations are due to
neuroglial overmigration into the arachnoid space, result-
ing in the formation of an extracortical neuroglial layer
responsible for the agyria and/or an irregular, ‘‘cobble-
stone’’ surface of the brain and ventriculomegaly. The
underlying mechanism is a disruption of the glia limitans,
the outermost layer of the brain.2–4 Cobblestone-LIS is
considered to be pathognomonic of a continuum of auto-
somal-recessive disorders resulting in ocular and muscular
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as ‘‘muscular congenital alpha-dystroglycanopathy with
brain and eye anomalies’’ (MDDGA). Aberrant post-transla-
tional modification of alpha-dystroglycan has been associ-
ated with mutations in at least six genes: POMT1 (MIM
607423), POMT2 (MIM 607439), POMGNT1 (MIM
606822), FKTN (MIM 607440), FKRP (MIM 606596), and
LARGE (MIM 603590).9–13 Another group designated as
having congenital muscular dystrophy-dystroglycanop-
athy withmental retardation (MDDGB) has been also asso-
ciated with mutations of these six genes (MIM 613155,
613156, 613151, 613152, and 606612). Except for LARGE,
these genes have also been implicated in the autosomal-
recessive limb-girdle muscular dystrophies (LGMD, re-
named MDDGC [MIM 609308, 613158, 613157, 611588,
and 607155, respectively) characterized by variable age
of onset, normal cognition, and no structural brain
changes.14–18
Our molecular and neurohistopathological study of fetal
cases of cobblestone-LIS demonstrated genetic heteroge-
neity and morphological diversity, along with some geno-
type-phenotype correlations.19,20 In our growing cohort of
90 cobblestone-LIS families, 42 (47%) unrelated cases re-
mained without any mutations in any of the six genes
known to be implicated, suggesting that other genes might
also be involved.
We therefore decided to use an SNP chip-based, genome-
wide linkage approach combined with an exome study in
two multiplex families (Figure S1 in the Supplemental
Data available online). All fetal cases were included in
the study on the basis of our diagnostic criteria of cobble-
stone-LIS as well as (1) neuroglial ectopia within the arach-
noid space, (2) abnormal cortical lamination, and (3) brain
stem and cerebellar dysplasia as described in Devisme
et al.20 Informed consent was obtained from parents in
accordance with French law and with the ethical standards
of the national committee on human experimentation.
Molecular screening was performed on genomic DNA
(gDNA) extracted from frozen fetal tissues according to
standard protocols. Genome-wide linkage studies were per-
formed by Affymetrix Genome-wide Human SNP-Array
250K in two multiplex cobblestone-LIS families (F1 and
F2) via Genotyping Console software (Affymetrix). Family
F1 is consanguineous and includes four affected fetuses.
Five runs of homozygosity (ROH) higher than 1 Mb were
shared by three of the affected fetuses studied and were
identified with the software PLINK21 in chromosomes 4
(two regions), 12, 15, and 20 (Table S1). The second multi-
plex family F2 is nonconsanguineous and includes three
affected fetuses. Multipoint linkage analysis was performed
with the software Merlin.22 Ten linkage regions that were
more than 2 Mb and had an LOD score >1 were found
on chromosomes 1, 6, 7 (two regions each), 10, 11, 17,
20, and 21 (Table S1). Illumina exome capture and next-
generation sequencing on an Illumina platform were per-
formed on samples from two affected fetuses of each of
the F1 and F2 families. After regions were filtered on the
basis of known variants, homozygosity for F1, two alleles1136 The American Journal of Human Genetics 91, 1135–1143, Decemutated for F2, and location in the region of ROH (F1)
or linkage regions (F2), a mutation in only one gene
was found to segregate in the two siblings for each
family (Table S2). In family F1, one homozygous variant,
c.795delG (p.Arg266Glyfs*8), was found in exon 5 of
TMEM5 (NM_014254.1 [MIM 605862]) in the ROH
region of chromosome 12. In family F2 an apparently
homozygous c.638T>G p.Met213Arg missense mutation
was found in exon 3 of ISPD (NM_001101426.3 MIM
614631]) in the largest linkage region on chromosome
7 (Table S1). Primers were designed in the flanking intronic
region of both genes (Table S3) for Sanger sequencing with
fluorescent di-deoxy capillary sequencing on an ABIPRISM
3130XL sequencer (Applied Biosystems). Sequence anal-
ysis was performed with Seqscape (Applied Biosystems)
software. This analysis confirmed that all the F1 fetuses
had inherited the homozygous c.795delG TMEM5 frame-
shift mutation from heterozygous parents. In the F2
family, the ISPD missense mutation was confirmed in
siblings and was found in the heterozygous state in
the mother only. Further molecular investigation by
qPCR in exon 3 (data not shown) identified a paternally in-
herited deletion, confirming compound heterozygosity
for a mutation and an intragenic deletion in family F2.
Data from the SNP array in this family indicated the
absence of any paternal contribution to the genotype of
the affected fetuses for three intragenic SNPs (SNP_A-
1826269, SNP_A-1948943, and SNP_A-1922943), which
was consistent with hemizygosity from hg19: chromo-
some7:16,306,467 (intron 6) to 16,344,268 (intron 4).
We therefore concluded that the size of the deletion in
this family encompasses at least exon 3 to exon 6.
In order to confirm the involvement of TMEM5 and
ISPD in cobblestone-LIS, we tested each coding exon and
intron/exon junction of the two genes for mutations by
direct gDNA SANGER sequencing in 40 cobblestone-LIS
families that were part of our cohort but that did not
have any mutation in the six genes known to be involved
in alpha-dystroglycanopathies. We found pathogenic
mutations in TMEM5 or ISPD in another eight families
(Table 1).We identified a total of five distinctTMEM5muta-
tions, including three frameshift (c.795delG [p.Glu265fs*
8], c.1064_1091del [p.Asp355Valfs*33], and c.279delA
[p.Gly94Glufs*33]) and two missense (c.1016A>G
[p.Tyr339Cys] and c.1019_1020delinsTT [p. Arg340Leu])
mutations, in five families (Figure 1A). In ISPD, we
identified nine distinct mutations, including two intra-
genic deletions, two nonsense mutations (c.256A>T
[p.Arg86*] and c.773C>A [p.Ser258*]), one splice mutation
(c.257þ2T>G), and four missense mutations (c.466G>A
[p.Asp156Asn], c.638T>G [p.Met213Arg], c.676T>C
[p.Tyr226His], and c.713C>T [p.Thr238Ile]), in five fami-
lies (Figure 1B). None of the missense variations were
present in the DbSNP, 1000 Genomes, or Exome Variant
Server data banks. All the amino acids concerned were
conserved from humans to zebrafish. Furthermore, we
used four different in silico prediction software packagesmber 7, 2012
Table 1. Summary of the Pathogenic TMEM5 (NM_014254.1) and ISPD (NM_001101426.3) Mutations Detected in This Study
Family Number,
Number of Sibs Consanguinity Gene Zygosity Nucleotide Variant
Amino Acid
Alteration
Exon(s)
Affected
Type of
Mutation
Panther
Prediction
pdeleterious
Align
GVGD
Class PolyPhen-2 SIFT
F1, 4 fetuses yes TMEM5 homozygous c.795 del G p.Arg266Glyfs*8 exon 5 frameshift NA NA NA NA
F7, 2 fetuses no TMEM5 homozygous c.1016A>G p.Tyr339Cys exon 6 missense 0.82 C65 probably damaging affected protein (0.00)
F8, 1 fetus no TMEM5 heterozygous c. 1019_1020del insTT p.Arg340Leu exon 6 missense 0.57 C65 probably damaging affected protein (0.00)
c.1064_1091del p.Asp355Valfs*33 exon 6 nonsense NA NA NA NA
F9, 1 fetus no TMEM5 heterozygous c.1016A>G p.Tyr339Cys exon 6 missense 0.82 C65 probably damaging affected protein (0.00)
c.1064_1091del p.Asp355Valfs*33 exon 6 frameshift NA NA NA NA
F10, 1 fetus ? TMEM5 homozygous c.279 delA p.Gly94Glufs*33 exon 2 frameshift NA NA NA NA
F2, 3 fetuses no ISPD heterozygous c.638T>G p.Met213Arg exon 3 missense 0.67 C65 probably damaging affected protein (0.03)
heterozygous deletion deletion exons 3 to
6 at least
gene deletion NA NA NA NA
F3, 2 fetuses yes ISPD homozygous c.466G>A p.Asp156Asn exon2 Missense 0.64 C15 probably damaging affected protein (0.00)
F4, 1 fetus no ISPD heterozygous c.713C>T p.Thr238Ile exon4 Missense 0.22 C65 probably damaging affected protein (0.01)
c.256A>T p.Arg86* exon1 Nonsense NA NA NA NA
F5, 1 fetus no ISPD heterozygous c.257þ2T>G * exon1 Splicing defect NA NA NA NA
c.773C>A p.Ser258 exon4 Nonsense NA NA NA NA
F6, 1 fetus no ISPD heterozygous c.676T>C p.Tyr226His exon3 Missense 0.45 C65 probably damaging tolerated (0.43)
deletion deletion Ex4 to ex6 Gene deletion NA NA NA NA
Panther: the probability that a given variant will cause a deleterious effect is estimated by pdeleterious such that a subPSEC score (substitution position-specific evolutionary conservation score based on an alignment of evolu-
tionarily related proteins) of 3 corresponds to a pdeleterious value of 0.5. Phenotype prediction for Align GVGD class C65 corresponds to "most likely interferes with function." PolyPhen-2 extracts various sequences and
structure-based features of the substitution site and feeds them into a probabilistic classifier. For the SIFT score, the amino acid substitution is predicted to be harmful if the score is %0.05 and is predicted to be tolerated
if the score is >0.05. NA ¼ not applicable.
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Figure 1. Diagram of the ISPD and TMEM5 Exon-Intron Gene Structure
All the pathogenic changes identified in this study (bold) and in two previous ISPD studies, Roscioli et al., 201230 (l) and Willer et al.,
201231 (l l) are included.(Polyphen, Panther, SIFT2, and Align GVGD) to evaluate
the potential effect on protein function. All missense
changes were predicted as being pathogenic by at least
two out of four software packages (Table 1). Segregation of
identified potentially disease-causing variants was per-
formed in each available family member, and autosomal-
recessive transmission was confirmed. In family F5,
c.257þ2T>G in ISPD appeared to be inherited de novo
because it was not found in either parent’s DNA. Paternity
was confirmed by the Power Plex 16 system (Promega, Ca,
USA), and allele-specific amplification was ruled out by
PCR with two different pairs of primers. Two mutations
in TMEM5 were found, in each case in two unrelated
families: c.1016A>G (p.Tyr339Cys) in F7 and F9 and
c.1064_1091del (p.Asp355Valfs*33) in F8 and F9. We
looked for a founder effect for these families by haplotype
analysis with four microsatellite markers in the vicinity of
TMEM5 and found a common haplotype for one allele for
each of the two unrelated families, suggesting that these
individuals could share the same ancestral chromosome
segment. In the nonconsanguineous family F7, in which
affected individuals had a homozygous TMEM5mutation,
parental DNAs were not available. We therefore confirmed
homozygosity by qPCR, which excluded a heterozygous
deletion.
Both the genes we identified in this study seem to
be functionally related to glycosylation. TMEM5 encodes
a 443 amino acid, type II transmembrane protein of1138 The American Journal of Human Genetics 91, 1135–1143, Deceunknown function. The protein contains a signal anchor
for a type II membrane protein encoded by amino acids
10–30, a cytoplasmic domain encoded by amino acids
1–9, and an extracellular domain encoded by amino acids
31–443.23 Interestingly, TMEM5 contains a domain that
has some similarities to exostosin (amino acids 218–353),
which is a domain found in EXT1. EXT1 codes for a glyco-
syltransferase required for the biosynthesis of heparan
sulfate24 and is a putative tumor suppressor gene involved
in multiple type-I exostoses (MIM 133700).25 A BlastP
analysis identified a region of 19% identity with EXT1,
which contains an aspartic acid-any amino acid-aspartic
acid (DXD) motif that is present in many glycosyltrans-
ferases and is critical for catalytic function thought to
be essential for binding the UDP-sugar donor through
the coordination of a divalent cation, Mn2þ 26,27 (Fig-
ure S2). Furthermore, EXT1 contains three other conserved
DXD motifs, but substitutions (Arg340Ser, Arg340His, or
Arg340Leu; and Arg280Gly or Arg280Ser) that have been
shown to result in defective heparan sulfate biosynthesis
cluster around the second DXD motif in this region of
homology with TMEM528,29 (Figure S2). Interestingly,
three out of the five TMEM5 mutations identified in our
study are also located in the exostosin domain (Figures
1A and 2). TMEM5 is therefore thought to be a transmem-
brane protein with a glycosyltransferase function.
Concerning ISPD, two recent independent studies simul-
taneously reported mutations in ISPD in postnatal WWSmber 7, 2012
Figure 2. Results of Molecular Diagnosis of Cobblestone-LIS
Fetuses
(A) Proportion of cases diagnosed after this study in our cohort of
90 cobblestone-LIS fetuses.
(B) Contribution of alpha-dystroglycanopathy gene mutations in
our 58 diagnosed cobblestone-LIS fetuses.cases (MDDGA7 [MIM 614631]).30,31 ISPD encodes an iso-
prenoid-synthase-domain-containing protein and belongs
to the super-family of nucleotide diP-sugar transferases
(amino acids 47–278). In plants, protozoa, and some
bacteria, ISPD is part of the methylerythritol phosphate
(MEP) pathway that leads to the polyisoprenoid alcohols
(dolichols and polyphenols).32 This MEP pathway in-
volving ISPD ismissing in animals,whichuse an alternative
ISPD-independent mevalonate pathway for isoprenoid
synthesis.33,34 The specific role of ISPD in humans is there-
fore unclear, but it is likely that ISPD synthesizes a new
nucleotide sugar that could be incorporated into alpha-dys-
troglycan O-glycan.30 Assays on fibroblasts derived from
ISPD-mutated WWS subjects complemented with wild-
type ISPD restored alpha-dystroglycan glycosylation.31
Furthermore, the knockdown presentation in zebrafish
reflected the WWS semiology, including hydrocephalus,
reduced eye size, andmuscle degeneration.30Glycosylation
of alpha-dystroglycanwas reduced in zebrafish embryos in-
jected with an dose of ISPD antisense morpholino oligonu-
cleotides (MOs) sufficient to knock down ISPD isoforms.
Coinjection with subeffective doses of FKTN or FKRP MO
reduced glycosylation more than injecting subeffective
doses of ISPD, FKTN, or FKRP MO alone.30 These findings
support a cooperative interaction between ISPD and both
FKTN and FKRP in alpha-dystroglycan glycosylation.
The ISPDmutations identified here are newly described,
apart from the deletion of exons 3 to 6, which was previ-The American Jouously described by Roscioli et al..30 Figure 1B shows a
recapitulation including previously published mutations.
Interestingly, the deletion of exons 3 to 6 in ISPD is located
in a known CNV (hapMap variation_2683: four observed
losses in 270 control samples, corresponding to a carrier
frequency of 1.5%). The frequency of the CNV does not
exclude its having a role in a rare disease, but it is possible
that homozygosity leads to embryonic lethality, similar to
that known for another glycosylation-related disease,
PMM2-CDG (MIM 212065), and to frequent p.Arg141His
mutation,35 which could explain the discrepancy between
the relatively high frequency of this variation and the low
frequency of cobblestone-LIS.
So far, only three out of the six genes mutated in alpha-
dystroglycanopathies have a clearly established function;
these are POMT1, POMT2, and POMGNT1, the genes en-
coding the three glycosyltransferases involved in early
steps of alpha-dystroglycan O-mannosylation. The func-
tion of Fukutin-related protein (FKRP) and fukutin
(FKTN) remains unknown. Both are Golgi-resident pro-
teins, and FKRP is required for the posttranslational modi-
fication of alpha-dystroglycan in the Golgi apparatus.36
Fukutin-related protein resides in the Golgi cisternae of
skeletal muscle fibers and forms disulfide-linked homo-
dimers via an N-terminal interaction.37 Fukutin seems to
bind the core area of alpha-dystroglycan during glycosyla-
tion.38 The exact function of LARGE is also unknown, but
the overexpression of LARGE restores O-glycosylation of
alpha-dystroglycan in cells of individuals with POMT1,
POMGNT1, LARGE, or FKTN mutations.39 LARGE is in-
volved in a phosphorylation process of the O-glycosyl
alpha-dystroglycan, which is required for laminin binding
and occurs on a specific Thr317 or Thr319 of the mucin-
like domain of alpha-dystroglycan.40,41 It has also been
shown that LARGE induces the functional glycans in a
DPM2- and O-mannosylation-dependent manner.42 Like
the other genes involved in alpha-dystroglycanopathies,
the two genes identified in this study are thought to be
glycosyl or nucleotide diP-sugar transferases, on the basis
of their similarities with known related domains.
In our previous study, we proposed a new classification
of cobblestone-LIS in three subtypes depending on the
severity of cortical malformations. In our classification,
the most severe form, called cobblestone-LIS(A), is usually
linked tomutations in POMT1 (34%) and POMT2 (8%); the
least severe, cobblestone-LIS(C), is linked to POMGNT1
mutations; and an intermediate type, cobblestone-LIS(B),
is linked to LARGE mutations.20 TMEM5 and ISPD muta-
tions were found in cobblestone-LIS(A), associated with
occipital neural-tube defects, facial clefts, visceral malfor-
mations, and gonadal dysplasia (Table 2). It is noteworthy
that neural-tube defects, visceral malformations, and
gonadal dysplasia were frequently observed in TMEM5-
mutated cases (5/7 cases) but were absent in ISPD-mutated
fetuses. In our previous study, we showed that visceral
malformations were observed in almost half of the cases
with POMT1 mutations (9/22) and in most of cases withrnal of Human Genetics 91, 1135–1143, December 7, 2012 1139
Table 2. Clinical Data of ISPD- and TMEM5-Mutated Cobblestone-Lissencephaly Fetal Cases Identified in This Study
Gene Fetus
Devisme et al., 201220
NTD
Limb
Deformations
Gonadal
Dysgenesis
Visceral
Malformation
Brain Vascular
Anomalies
Cerebellar Dysplasia Retinal Dysplasia
ECL/CP
Extension Severity Extension Severity
Family Number Fetus Number Diffuse Focal Major Minor Diffuse Focal Major Minor
ISPD F2-1 F26 35 þ - - - >1 þ þ þ þ
ISPD F2-2 F26 67 þ þ þ þ >1 þ þ þ þ
ISPD F2-3 F26 68 þ - - þ >1 þ þ þ þ
ISPD F3-1 F23 29 - - - - þ >1 þ þ þ þ
ISPD F3-2 F23 30 - þ - - >1 þ þ NE NE NE NE
ISPD F4 F25 34 - þ - - >1 þ þ þ þ
ISPD F5 F55 69 þ - - - þ >1 þ þ NE NE NE NE
ISPD F6 / / - - - - NE NE NE NE NE NE NE
TMEM5 F1-1 F1 1 þ - þ þ >1 þ þ NE NE NE NE
TMEM5 F1-2 F1 2 - - þ þ >1 þ þ þ þ
TMEM5 F1-3 F1 3 þ - - - >1 þ þ þ þ
TMEM5 F1-4 / / NE NE NE NE NE NE NE NE NE NE NE NE NE
TMEM5 F7-1 F24 31 þ - þ þ >1 þ þ þ þ
TMEM5 F7-2 F24 32 þ - - - >1 þ þ þ þ
TMEM5 F8 F27 36 - - þ - >1 þ þ þ þ
TMEM5 F9 F50 62 þ þ þ þ >1 þ þ þ þ
TMEM5 F10 F54 66 - - - - >1 þ þ NE NE NE NE
Abbreviations are as follows: NTD ¼ neural-tube defect; ECL/CP ¼ extracortical layer/cortical plate; and NE ¼ not evaluated.
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POMT2 mutations (4/5).20 POMT1 was frequently associ-
ated with cleft lip and cleft palate.20,43 POMT2 and
TMEM5 were frequently associated with gonadal dysgen-
esis, found in 3/5 of the POMT2 cases20 and 5/8 of the
TMEM5 cases. It is noteworthy that in two cases with
ISPD mutations, the neuropathological study revealed
severe vascular dysplasia and perfusion impairment,
leading to focal brain parenchyma necrosis.
An overview of mutated alpha-dystroglycanopathy
genes in our cohort of 90 cobblestone-LIS families is
provided in Figure 2. Altogether, mutations in POMT1
(n ¼ 24, 42%), POMT2 (n ¼ 10, 17%), POMGNT1 (n ¼
10, 17%), TMEM5 (n ¼ 5, 9%), ISPD (n ¼ 5, 9%), LARGE
(n ¼ 2, 3%), and FKRP (n ¼ 2, 3%) (Figure 2B) have now
been identified in 58 cobblestone-LIS families. TMEM5
and ISPD each accounted for almost 10% of the mutated
cases, which is consistent with the previously published
data for ISPD in postnatal WWS cases.30,31 Both genes
were involved three times more frequently than LARGE
in our series of cobblestone-LIS families and may therefore
be considered to be two additional important genes with
regard to this pathology. Our study raises the mutational
rate to 64% in our cohort and once more highlights the
importance of fetal pathological examination, not only
for accurate diagnosis and subsequent genetic counseling
but also for the classification of homogeneous groups
and genotype-phenotype correlations that considerably
accelerate molecular screening.
More recently, four other genes related to alpha-
dystroglycanopathies were reported, although they were
found in only a few individuals with mild myopathy.
Three of these genes are related to glycosylation, and the
fourth is the dystroglycan gene DAG1 itself (MIM
128239). One individual with dilated cardiomyopathy
and a low but normal IQ was found to have a mutation
in DPM3 (MIM 605951);44 two siblings with CMD and
mental retardation were found to harbor mutations in
DPM2 (MIM 603564);45,46 and four families with dilated
cardiomyopathy were reported to have DOLK (MIM
610746) mutations.47 Finally, two individuals were
found to carry a mutation inDAG1; one carried a heterozy-
gous deletion of a 2 MB region including DAG1,48 and
the other, with LGMD and cognitive impairment, had a
homozygous missense mutation.49 Considering the
numbers of individuals reported to date, these four genes
should be considered to be minor alpha-dystroglycanop-
athy genes.
The molecular basis of cobblestone-LIS remains unex-
plained in more than 36% (32/90) of our families (Fig-
ure 2A), suggesting either that some of the mutations of
these genes were not detected or that other genes remain
to be discovered. We studied all the genes by sequencing
and genomic assays with CGH array analysis or qPCR to
exclude intragenic rearrangements. Large-scale DNA rear-
rangements have now been identified in five genes associ-
ated with dystroglycanopathies (these genes are LARGE,
POMT1, POMT2, POMGnT1, and ISPD).30,50 In some cases,The American Jousuch as a recent LGMD case in which an alteration in the
POMGNT1 promoter was reported,51 mutations might be
located in noncoding sequences; in other cases, there
might be a deep intronic mutation, and so cDNA analysis
by RT-PCR will need to be performed.
In conclusion, TMEM5 and ISPD are two additional
important genes involved in cobblestone-LIS. They are
thought to be glycosyl or nucleotide diP-sugar transferases
and are responsible for the severe type A. Genotype-
phenotype correlation improves the efficiency of genetic
counseling through better orientation of molecular
screening on the basis of the clinical severity of the
cobblestone-LIS type. Our results do indeed suggest a
molecular diagnostic strategy pointing through POMT1,
POMT2, TMEM5, and ISPD in severe cobblestone-LIS
type A. Because six other genes have been shown to be
involved in the wide clinical spectrum of alpha-dystrogly-
canopathies, ISPD and TMEM5 will also be studied in less
severe clinical cases presenting a spectrum of defects
ranging from congenital muscular dystrophy (CMD) asso-
ciated with mental retardation and cerebellar malforma-
tion to mild limb girdle muscular dystrophy (LGMD)
with or without mental retardation. The same combina-
tion of an SNP array and exome sequencing in multiplex
or consanguineous families is now underway in the re-
maining unexplained cases and can be expected to lead
to the identification of so-far-unknown genes that con-
tribute to cobblestone-LIS.Supplemental Data
Supplemental data include two figures and three tables and can be
found with this article online at http://www.cell.com/AJHG.
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